Related Experiment Video

Updated: Mar 30, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.4K

The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma

Traci R Tuttle1, Michelle L Mierzwa2, Susanne I Wells3

  • 1Department of Cancer Biology, University of Cincinnati School of Medicine, Cincinnati, OH 45267, USA.

Cancer Letters
|November 10, 2015
PubMed

Insights

This study explores the cyclic GMP-protein kinase G (PKG) pathway for head and neck squamous cell carcinoma (HNSCC) treatment. Targeting this pathway with specific drugs significantly reduced cancer cell viability and tumor growth, offering new therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Head and neck squamous cell carcinoma (HNSCC) presents a significant challenge due to its aggressive nature and high mortality.
  • Current HNSCC treatments have seen limited advancement over the past 30 years, often leading to substantial patient morbidity.
  • The cyclic GMP (cGMP)/protein kinase G (PKG) signaling pathway, crucial in various cellular functions, has shown antineoplastic potential in other cancers but remains underexplored in HNSCC.

Purpose of the Study:

  • To investigate the role and therapeutic potential of the cGMP/PKG pathway in head and neck squamous cell carcinoma.
  • To evaluate the effects of soluble guanylate cyclase (sGC) activators and phosphodiesterase type 5 (PDE5) inhibitors on HNSCC cell lines.
  • To assess the in vivo efficacy of targeting the cGMP/PKG pathway in HNSCC.

Main Methods:

  • Differential expression analysis of cGMP/PKG pathway components in four HNSCC cell lines.
  • Treatment of HNSCC cells with sGC activators and PDE5 inhibitors, assessing cell viability and apoptosis.
  • Pharmacological inhibition of PDE5 using Tadalafil and activation of sGC using BAY 41-2272, with PKG mediation confirmed.
  • Xenograft studies in athymic mice using CAL27-derived tumors to evaluate Tadalafil's in vivo anti-tumor effect.

Main Results:

  • Differential expression of key cGMP/PKG pathway elements was observed in HNSCC cell lines.
  • sGC activators and PDE5 inhibitors significantly decreased HNSCC cell viability and induced apoptosis.
  • The apoptotic effects were confirmed to be PKG-mediated for both the sGC activator BAY 41-2272 and the PDE5 inhibitor Tadalafil.
  • Tadalafil demonstrated significant tumor growth inhibition in a mouse model of HNSCC.

Conclusions:

  • The cGMP/PKG pathway represents a promising therapeutic target for head and neck squamous cell carcinoma.
  • Repurposing existing drugs that activate sGC or inhibit PDE5 could offer novel and effective treatment strategies for HNSCC patients.
  • Further clinical investigation into these drug candidates for HNSCC is warranted.
Keywords:
HNSCCPDE5PKGTadalafilcGMPsGC

More Related Videos

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

20.1K
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

11.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K